We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry, FDA Debate Viability of Follow-On Biologics
Industry, FDA Debate Viability of Follow-On Biologics
October 4, 2005
The FDA can and should create an approval process for follow-on biologics, said pharmaceutical industry experts at the recent Generic Pharmaceutical Association (GPhA) conference, but an agency official countered that there is still a lot to learn about the complexity and risks of such drugs.